Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor | BMJ Neurology Open

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

This article has a correction. Please see:

Correction: Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor - October 01, 2022

Short report

Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Chen J, Nguyen M, Hu H, et al

Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor

BMJ Neurology Open 2022;4:e000285. doi: 10.1136/bmjno-2022-000285